newsfilter
← Earnings
Earnings Releases·

Intensity Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss increased to $3.5 million in Q3 2026 from $2.7 million in the prior year period, driven by a rise in R&D expenses to $2.4 million, while cash and cash equivalents declined to $8.5 million from $11.9 million at year-end 2025.
  • Clinical enrollment resumed in Q3 2026 for both the Phase 3 INVINCIBLE-3 Study (limited U.S. sites) and the Phase 2 INVINCIBLE-4 Study, with preliminary INVINCIBLE-4 data showing a 71% pathological complete response rate in Cohort A versus 42% in the control group.
  • The Company targets complete enrollment in the INVINCIBLE-4 Study by the end of 2027, with an IDMB safety review scheduled for Q1 2027, while simultaneously pursuing documentation to restart the INVINCIBLE-3 Study in the EU and Canada.
  • Capital activities included the establishment of a $60 million ATM facility in March 2026, raising $1.5 million in Q3 2026 and $3.2 million for the first nine months of the year.
Company
INTENSITY THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology